Skip to main content
Industry News
Amgen, Allergan tout positive results from Rituxan biosimilar trial

Amgen and co-collaborator Allergan released positive data from its second late-stage trial assessing their biosimilar candidate, ABP 798, in comparison to Roche's Rituxan, or rituximab, as a treatment for CD20-positive B-cell non-Hodgkin lymphoma. Results indicated the two drugs were comparable in terms of clinical equivalence, safety and immunogenicity.

Full Story: